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Abstract: In human cells, mitochondria provide the largest part of cellular energy in the form
of adenosine triphosphate generated by the process of oxidative phosphorylation (OXPHOS).
Impaired OXPHOS activity leads to a heterogeneous group of inherited diseases for which therapeutic
options today remain very limited. Potential innovative strategies aim to ameliorate mitochondrial
function by increasing the total mitochondrial load of tissues and/or to scavenge the excess
of reactive oxygen species generated by OXPHOS malfunctioning. In this respect, resveratrol,
a compound that conveniently combines mitogenetic with antioxidant activities and, as a bonus,
possesses anti-apoptotic properties, has come forward as a promising nutraceutical. We review
the scientific evidence gathered so far through experiments in both in vitro and in vivo systems,
evaluating the therapeutic effect that resveratrol is expected to generate in mitochondrial patients.
The obtained results are encouraging, but clearly show that achieving normalization of OXPHOS
function with this strategy alone could prove to be an unattainable goal.
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1. Introduction
Mitochondria are the powerhouses of human cells and generate the bulk of energy
necessary for cell maintenance and growth in the form of adenosine triphosphate (ATP),
through the process of oxidative phosphorylation (OXPHOS). The OXPHOS system consists of
five multiprotein complexes that associate with the inner mitochondrial membrane: complex I
(NADH: ubiquinone oxidoreductase), complex II (succinate: ubiquinone oxidoreductase), complex III
(ubiquinol: cytochrome c oxidoreductase), complex IV (cytochrome c oxidase), and complex V
(ATP synthase). Reducing equivalents are delivered via NADH, ubiquinol, and cytochrome c,
allowing high energy electrons to pass along the first four complexes, a process that releases the
energy needed to pump hydrogen into the inter-membrane space, converting O2 to H2O. The proton
gradient that develops between the mitochondrial matrix and the inter-membrane space generates
an electrochemical membrane potential that drives the conversion of ADP to ATP by complex V.
Both chromosomal and mitochondrial DNA (mtDNA)-encoded genes are essential for OXPHOS
functioning. The mitochondrial genome is polyploid with multiple copies of mtDNA present within
each individual mitochondrion and can exhibit heteroplasmy, i.e., the co-existence of different genetic
variants within the same cell. The mtDNA encodes for 13 structural subunits of complexes I, III, IV,
and V and for 2 rRNAs and 22 tRNAs necessary for mitochondrial protein translation. All other
components of the OXPHOS machinery are encoded by the nuclear genome, and the latter controls all
other aspects of mitochondrial functioning and nuclear–mitochondrial communication [1]. There are
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more than 70 nuclear genes encoding structural OXPHOS components. A myriad of other nuclear gene
products are involved in regulation, post-translational modification, signaling, importation, folding,
and assembly of the OXPHOS components. All these factors are equally essential for proper OXPHOS
functioning [2].
Mitochondrial OXPHOS defects are estimated to affect approximately 1 in 5000 children born,
and are associated with a broad spectrum of clinical manifestations ranging from mild myopathy to
lethal multi-system disorders [3]. Isolated complex I deficiency [4] and mtDNA depletion syndrome [5]
are the most frequent underlying molecular causes. Due to the dual origin of the genes involved,
and the specific nature of the mitochondrial genome, OXPHOS defects are complex. In case of
heteroplasmic mtDNA mutations, disease develops only if the mutant-load of a tissue reaches the
threshold required to reduce OXPHOS capacities. The amount of mutant mtDNA determines severity
of symptoms ranging from mild disease to debilitating and lethal conditions. Point mutations are
mostly heteroplasmic, displaying considerable clinical heterogeneity. They may occur within protein,
tRNA, or rRNA genes, but more than half of disease-related point mutations reported are located
within mt-tRNA genes. Over 80% of patients with mitochondrial encephalomyopathy, lactic acidosis
and stroke-like episodes (MELAS) have the m.3243A>G mutation in the MT-TL1 gene, and myoclonic
epilepsy and ragged red fibers (MERRF) is caused most commonly by an m.8344A>G point mutation in
the MT-TK gene. Neuropathy, ataxia, and retinitis pigmentosa (NARP) is usually due to the MT-ATP6
m.8993T>G mutation [6].
While we await the coming of age of gene therapies for human monogenic diseases,
the development of effective pharmacological therapies for OXPHOS deficiencies has been extremely
limited so far [7]. Nutritional supplementation has been tried: coenzyme Q10, vitamin C, creatine,
sodium dichloroacetate, sodium pyruvate, and L-arginine. This generated some evidence of improved
symptoms or slower progression in subsets of patients, but a pressing need for frontline treatments
remains. A possible therapeutic approach for OXPHOS deficiencies is to increase the number of
mitochondria per cell, which can result in greater capacities to produce ATP. Another strategy is to
reduce the cell-damaging side effects of dysfunctional OXPHOS, i.e., the generation of harmful reactive
oxygen species (ROS) and cell death. Along this line, resveratrol (RSV) seems an exquisite candidate,
as the compound has been observed to possess mitogenetic, antioxidant, and anti-apoptotic activities.
2. The Stimulatory Effect of Resveratrol on Mitogenesis and Mitochondrial Interconnections
Mitochondrial biogenesis is a highly synchronized process driven by changing energetic
demands. Regulation is governed by a complex system of transcription factors and co-activators,
in which the peroxisome proliferator-activated receptor-γ coactivator α (PGC-1α) functions as a
master regulator [8,9]. Stimulation of PGC-1α activity results in increased mitochondrial mass and
function. PGC-1α expression in its turn is controlled by the peroxisome proliferation activated
receptor family (PPAR) [10] and by deacetylation mediated by NAD+-dependent protein deacetylase
sirtuin-1 (SIRT-1) [11,12]. In addition to sufficient amounts of mitochondria to achieve desirable
ATP levels in the cell, interconnection of mitochondria into a complex cell-spanning network
is another requisite for proper OXPHOS functioning. The mitochondrial network takes shape
through the dynamic equilibrium between fusion and fission of the organelles, complexly regulated
by changing cellular conditions [13] through the activities of mitofusins (MFN) and dynamins.
Mitochondrial interconnection promotes the sharing of constituents and positively influences
overall efficiency of OXPHOS [14]. Fragmented mitochondria are known to display diminished
respiratory capacity [15].
Higher mtDNA content and increased mitogenesis have been suggested to improve the
disease phenotype of patients with OXPHOS deficiencies. Mitochondrial proliferation was
shown to protect mutation carriers from developing Leber’s hereditary optic neuropathy [16].
Heteroplasmic OXPHOS defects benefit from intensive exercise, an effect attributed to PGC-1α-induced
mitochondrial stimulation [17]. In cybrids harboring the classical m.3243A>G MELAS mutation,
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PGC-1α overexpression improved OXPHOS complex III and complex IV deficiency [18].
Evidence accumulates of a positive effect of RSV on the process of mitogenesis mediated via PGC-1α
stimulation. By inhibiting phosphodiesterases, RSV has been observed to activate SIRT-1 and
subsequently PGC-1α [19]. Doses of 25 µM RSV have been shown to activate PGC-1α in mouse
myoblasts, a process mediated via the metabolic sensor AMP-activated kinase (AMPK) and subsequent
SIRT-1 activation [20]. In primary human coronary arterial endothelial cells, 10 µM RSV for 48 h
significantly increased mitochondrial mass and mtDNA content, through SIRT-1-mediated induction
of the mitogenetic factors PGC-1α, TFAM and nuclear respiratory factor-1 [21]. In mouse myoblasts and
embryonic fibroblasts, 20 µM RSV for 48 h stimulated mitochondrial fusion through increased MFN2
expression, resulting in a highly branched mitochondrial network [22]. In vivo, a significantly increased
mitochondrial biogenesis was detected in RSV-fed mice [23], an effect comparable to the one achieved
by PGC-1α overexpression [24]. In addition, RSV treatment of cultured skin fibroblasts obtained
from healthy individuals was shown to stimulate the expression of mitochondrial transcription
factor (TFAM) [25]. TFAM is a key factor for mtDNA replication and repair and thus crucial for
mitochondrial proliferation.
3. The Regulatory Effect of Resveratrol on OXPHOS
In addition to the higher OXPHOS levels that can be achieved by increasing the mitochondrial
load, RSV may also interact directly with the OXPHOS chain. Physical association between RSV
and OXPHOS complex I has been documented. RSV enters the nucleotide-binding pocket of the
NADH dehydrogenase module, competing with NAD+ fixation [26]. Interactions, however, seem
to display a complex effect upon OXPHOS activities. NADH oxidation increases with low doses
up to 5 µM RSV, while high doses of 50 µM inhibit complex I activity. In vivo, 40 mg/kg/day
of RSV significantly increased complex I activity in young mice but not in mice over 22 months
old [27]. It has been reported that 100 µM RSV inhibited complex III activity, by competing for binding
with co-enzyme Q [28]. Treatment with 20 µM RSV for 48 h increased basal and carbonyl cyanide
p-triflouromethoxyphenyl-hydrazone (FCCP) uncoupled respiration rates in mouse myoblasts [22],
pointing to a positive effect on complex I to IV activity. Low concentrations (pico to nanoM) activate
complex V [29], while doses in the microM range inhibit ATP synthesis [30].
4. The Protective Effect of Resveratrol on Oxidative Cell Stress
In the mitochondria, ATP and electrons are produced from NADH and succinate, reducing
O2 to H2O. As a consequence of electron leakage during mitochondrial respiration, O2− can be
generated through univalent reduction of molecular oxygen. Reactive oxygen species (ROS), which
are short-lived molecules with unpaired electrons, are generated. Although low concentrations of
ROS serve as second messengers regulating cellular processes, higher concentrations cause oxidative
damage. To prevent these harmful effects, aerobic organisms have put a complex array of defensive
systems into place, comprising scavenging enzymes and antioxidant agents. In response to oxidative
damage, the mitochondrial stress response protein sirtuin-3 (SIRT-3) induces forkhead box O3 (FoxO3a)
translocation toward the nucleus, activating antioxidant defense mechanisms through the upregulation
of PGC-1α and superoxide dismutase 2 (SOD2). SIRT-3 can directly activate SOD2 via protein/lysine
deacetylation [31]. Antioxidant defenses tend to decrease with age, and RSV supplementation has been
shown to compensate the SOD2 reduction in mice aged over 22 months [27]. RSV has been reported to
trigger cellular anti-oxidant defense mechanisms in aging endothelial cells [32]. In cultured primary
human coronary arterial endothelial cells, RSV concentration-dependent increases of the transcriptional
activity of nuclear factor-E2-related factor-2 (Nrf2) have been observed [33]. Nrf2 regulates the
expression of numerous ROS detoxifying genes. These defense mechanisms also salvage mitochondria
from injury caused by hypoxic ischemia, as recently reviewed in [34]. One established experimental
model for studying oxidative stress consists of Cd exposure. Using this model, further evidence
has been gathered that RSV is capable of restoring ROS homeostasis within cells. In mouse renal
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tubular epithelial cells, pre-treatment for 2 h with 5 µM RSV protected against Cd-induced ROS
elevation and OXPHOS dysfunction. Knockdown experiments with SIRT-3 siRNA have been observed
to abolish the protective effect, illustrating the key role such a factor plays [35]. SIRT-3 is known
to bind and deacetylate several metabolic and respiratory enzymes that regulate mitochondrial
ROS production. [36]. In vivo experiments showed that RSV also protected against Cd-induced
perturbations of spermatogenesis and histology in mice [37].
5. The Anti-Apoptotic Effect of Resveratrol
Apoptosis or programmed cell death is a highly regulated process that is detrimental to the
individual cell, yet possesses crucial constructive potential for tissue development and homeostasis [38].
Mitochondria have a leading role in triggering this process. The association of various regulatory
factors including proteins from the B-cell lymphoma 2 (Bcl-2) family, steers, together with the outer
mitochondrial membrane, an apoptotic signal cascade transduction either by inducing or by preventing
membrane permeabilization. Signaling cell death starts with mitochondrial transmembrane potential
depolarization and the release of mitochondrial cytochrome c into the cytosol, which activates cellular
proteases (caspases) and leads to subsequent cell apoptosis [39]. Mitochondrial disease has been linked
to increased apoptosis. Skeletal muscle tissues of patients with single mtDNA deletions and tRNA
point mutations display prominent histologic apoptotic features. Interestingly, the tRNA mutation
load matches the degree of apotosis as well as the severity of phenotype [40], identifying apoptosis
as a plausible contributing pathogenic mechanism of tissue damage in mitochondrial disorders.
Polyphenols have been shown to protect the mitochondrial membrane. RSV pre-incubation prevents
hen egg white lysozyme-induced permeabilization in purified mitochondria [41]. An anti-apoptotic
effect of RSV has been shown in mouse renal tubular epithelial cells, where pre-treatment with 5 µM
RSV reduced extracellular signal-regulated kinases1/2 phosphorylation and prevented Cd-induced
activation of caspase-3 activity and Bcl-2-associated X protein (Bax) expression [35].
6. Resveratrol Supplementation as a Treatment for Mitochondrial Disorders
RSV could have its place in a combined therapeutic strategy for boosting OXPHOS in deficient
patients, by both stimulating mitochondrial proliferation and reducing cytotoxic ROS by-products and
apoptotic cell signaling (Figure 1).
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Figure 1. Summary of prop sed beneficial eff cts of resveratrol on mitochondrial respiration and
cell survival. Abbreviations: AMP-activated protein kinase (AMPK); B-cell lymphoma 2-associated
X protein (Bax); extracellular signal-regulated kinase (E K); nuclear factor-E2-regulated factor-2
(Nrf2); phosphodiesterase (PDE); peroxisome proliferator-activated receptor-γ coactivator α (PGC-1α);
resveratrol (RSV); reactive oxygen species (ROS); sirtuin 1 (SIRT-1); super oxide dismutase 2 (SOD2).
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We present here a summary of the results of experiments using primary cultured skin fibroblasts
from patients with homoplasmic mtDNA and homozygous or heterozygous nuclear DNA mutations
in Table 1.
Table 1. In vitro results of resveratrol treatment outcome in cultured skin fibroblasts from patients with
oxidative phosphorylation defects.
Mutation Deficiency Regimen Outcome Reference
m.3243A>G TL1 not reported 0.01 µM 24 h basal OCR and ATPproduction significantly ↑ [42]
m.8344A>G TK not reported 0.01 µM 24 h basal OCR and ATPproduction significantly ↑ [42]
m.8993T>G ATP6 not reported 0.01 µM 24 h basal OCR and ATPproduction significantly ↑ [42]
c.611A>G NDUFV1 complex I 75 µM 48 h 72 h OCR and complex Iactivity significantly ↑ [25]
c.640G>A NDUFV1 complex I 75 µM 48 h 72 h normalized complex I activity [25]
c.1294G>C NDUFV1 complex I 75 µM 48 h 72 h OCR and complex Iactivity significantly ↑ [25]
c.1129G>A NDUFV1 complex I 75 µM 48 h 72 h no change [25]
c.1142A>G c.11G>A
NDUFV1 complex I 75 µM 48 h no change [43]
c.1156C>T NDUFV1 complex I 75 µM 48 h basal OCR, ATP production andcomplex I activity significantly ↑ [43]
c.1157G>A NDUFV1 complex I 75 µM 48 h 72 h no change [25]
c.54X>A c.207dup
NDUFV2 complex I 75 µM 48 h basal OCR significantly ↑ [43]
c.120+5_120+8delGTTA
NDUFV2 complex I 75 µM 48 h 72 h
basal OCR, ATP production and
complex I activity significantly ↑ [43]
gene deletion
NDUFS1 complex I 75 µM 48 h 72 h no change [25]
c.683T>C c.755A>C
NDUFS1 complex I 75 µM 48 h basal OCR significantly ↑ [43]
c.721C>T NDUFS1 complex I 75 µM 48 h 72 h no change [25]
c.1139A>T c.63+6T>G
NDUFS1 complex I 75 µM 48 h no change [43]
c.875T>C c.1328T>A
NDUFS2 complex I 75 µM 48 h
basal OCR and complex I
activity significantly ↑ [43]
c.875T>C c.353G>A
NDUFS2 complex I 75 µM 48 h no change [43]
c.1237T>C NDUFS2 complex I 75 µM 48 h no change [43]
c.434C>T NDUFS3 complex I 75 µM 48 h 72 h no change [25]
c.291delG NDUFS4 complex I 75 µM 48 h basal OCR, ATP production andcomplex I activity significantly ↑ [43]
c.67del NDUFS6 complex I 75 µM 48 h basal OCR significantly ↑ [43]
c.17-1167C>G
NDUFS7 complex I 75 µM 48 h no change [43]
c.434G>A NDUFS7 complex I 75 µM 48 h basal OCR and complex Iactivity significantly ↑ [43]
unknown complex I 75 µM 48 h 72 h normalized complex I activity [25]
unknown complex I 25 µM 72 h no change [44]
c.296A>G C8orf38 complex I 75 µM 48 h 72 h no change [25]
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Table 1. Cont.
Mutation Deficiency Regimen Outcome Reference
c.997C>T EFTs complex I & IV 25 µM 72 h ATP production and mitochondrialcontent significantly ↑ [44]
c.509G>A MRPS22 complex I & IV 25 µM 72 h ATP production significantly ↓ROS significantly ↑ [44]
unknown complex II 100 µM 48 h no change [45]
c.622G>T NFU1 complex II 100 µM 48 h no change [45]
c.1663G>A Fp complex II 100 µM 48 h complex II and CSactivity significantly ↑ [45]
unknown complex IV 100 µM 48 h no change [45]
unknown complex IV 100 µM 48 h complex II and CSactivity significantly ↑ [45]
unknown complex IV 100 µM 48 h complex II and CSactivity significantly ↑ [45]
c.312_321del insAT
SURF-1 complex IV 100 µM 48 h
complex IV and CS
activity significantly ↑ [45]
c.312_321del insAT
SURF-1 complex IV 100 µM 48 h no change [45]
c.312_321del insAT
SURF-1 complex IV 100 µM 48 h CS activity significantly ↑ [45]
c.312_321del10insAT
SURF-1 complex IV 75 µM 48 h 72 h no change [25]
c.539G>A SURF-1 complex IV 75 µM 48 h 72 h no change [25]
c.845_846delCT
SURF-1 complex IV 100 µM 48 h no change [45]
c.612C>A complex IV 75 µM 48 h 72 h no change [25]
c.36142203C>T
COX6B1 complex IV 25 µM 72 h
mitochondrial content and
ROS significantly ↑ [44]
c.612C>A COX10 complex IV 75 µM 48 h 72 h complex IV activity significantly ↑ [25]
unknown Complex IV 25 µM 72 h no change [44]
unknown complex IV 100 µM 48 h complex II and CSactivity significantly↑ [45]
Increases are indicated with ↑, decreases with ↓. Abbreviations: citrate synthase (CS); cytochrome c-oxidase (COX);
elongation factor for mitochondrial translation (EFT); mitochondrial ribosomal protein (MRP); NADH:ubiquinone
oxidoreductase core subunit (NDUF); iron-sulfur cluster scaffold (NFU); oxygen consumption rate (OCR);
oxidative phosphorylation (OXPHOS); surfeit locus protein-1 (SURF-1); tRNA lysine (TK); tRNA leucine (TL).
Only one report is available that assays the effect of RSV on cells with mtDNA defects.
In human skin fibroblasts from patients with homoplasmic MT-TL1, MT-TK, and MT-ATP6 gene
mutations, 0.01 µM RSV administered for 4 days increased basal oxygen consumption rates and
ATP production [44]. A study with cultured skin fibroblasts from patients with OXPHOS complex I
and complex IV deficiency showed stimulated mitochondrial biogenesis, as visualized by increased
mitotracker green staining intensity and TFAM protein expression, and increased OXPHOS protein
levels, which resulted in the correction of the deficiency (measured through oxygen uptake rates) in
6 out of 16 patient cell lines [25]. In cells from patients with complex I deficiency that improved with
RSV, treatment resulted in normalized lactate/pyruvate cell supernatant ratios, pointing to restored
cellular NADH/NAD ratios. OXPHOS-deficient patients often present with severe lactic acidosis [46].
Another study investigated fibroblasts from 13 patients with nuclear defects causing OXPHOS complex
I deficiency, and showed a benefit in administering 75 µM RSV for 48 h in eight patient cell lines.
In five cell lines, ROS levels were found to be increased as compared to cells from healthy individuals.
RSV treatment significantly reduced ROS levels in four of these patient cell lines, an effect that was
attributed to increased SOD2 protein levels established through SIRT-3 activation [43]. Our own study
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assayed the effect of RSV in cultured skin fibroblasts obtained from patients with either complex
II or isolated complex IV deficiency. Although 48 h treatment with 100 µM resveratrol was able to
significantly increase complex II and complex IV activities in control cells, activity of the deficient
complex was significantly increased in only one of the complex II deficient patients and in none
of the complex IV patients [45]. In contrast to the mostly encouraging studies above, treatment of
cultured skin fibroblasts from five patients with complex I and/or complex IV deficiency with 25 µM
RSV for 72 h was reported to have no or even negative effects upon mitochondrial proliferation,
ATP production, and ROS generation [44].
The above-mentioned studies reveal that responses to RSV are not uniform but highly
cell-line-dependent. Evidence points toward the magnitude of the OXPHOS defect as an important
determinant of beneficial effects that can be registered in cultured fibroblasts. The cohort with varying
degrees of OXPHOS deficiency reported by Lopes Costa et al. exhibited significantly increased complex
I activities in five cell lines, normalizing values in two of those, while complex IV activity increased
significantly only in a cell line carrying a COX10 defect. Interestingly, mean residual complex I and
complex IV activities were all above 40% of normal controls in the responsive and below 40% in the
non-responsive cell lines [25]. Mathieu et al. reported that the complex I deficient cell lines, which
improved in response to RSV, all had residual complex activities between 56% and 28% of normal
fibroblasts [43]. Our own study described the significant RSV-induced increase of complex II activity
in a patient with residual activities above 20% of normal values, while the two complex II deficient cell
lines exhibiting residual activities below 20% of normal did not respond [45].
In summary, the studies published so far indicate a defect-dependent response in cultured skin
fibroblasts, displaying an approximately 50/50 chance of deficient cells benefitting from RSV treatment.
Data indicate that cells might still require substantial remaining residual OXPHOS activities to generate
a response.
7. Conclusions
RSV displays multiple interactions with mitochondrial activity and unmistakably possesses
mitogenetic, anti-oxidant, and anti-apoptotic effects. The compound is a small lipophilic molecule that
can cross cell barriers and penetrate cell organelles with ease. Therapeutic success appears, however,
to be variable and dependent on many factors, which include the severity of the underlying defect
and the administered dose. Importantly, a threshold of residual OXPHOS activity seems necessary
for enabling RSV to generate a response. Therefore, the life-saving potential of RSV in mitochondrial
disease seems extremely limited. RSV could, however, be beneficial to individual patients when
used as a supportive therapeutic supplement and as part of a multi-component therapy. In support,
supplements of 500 mg/day RSV have been shown to enhance exercise-induced improvement of
muscle capacities in subjects 65 years or older [47].
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